Home DNA test results from 23andMe to help develop drugs

Pharmaceutical giant GlaxoSmithKline has invested $300 million into home DNA testing company 23andMe, allowing it to develop drugs based on human genetics.
The four-year agreement allows GSK access to 23andMe's vast database to accelerate its drug research and development work. 
SEE ALSO: The first 3D, full-color X-rays will weird you out
More than 5 million customers use 23andMe's saliva kit to profile their genes. The kits allow users to uncover insights about their ancestry, other people